# EDGAR Filing Document

**Accession Number:** 0001421876
**File Stem:** 0001171843-26-003984
**Filing Date:** 2026-6
**Character Count:** 7896
**Document Hash:** 101422cfc6af97327a5dce8b1f53211b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-003984.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001171843-26-003984

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260608

**FILED AS OF DATE**: 20260609

**DATE AS OF CHANGE**: 20260609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lakefront Biotherapeutics NV
- **CENTRAL INDEX KEY:** 0001421876
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37384
- **FILM NUMBER:** 261074511

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SCHALIENHOEVEDREEF 20T
- **CITY:** 2800 MECHELEN
- **PROVINCE COUNTRY:** C9
- **BUSINESS PHONE:** 3215342900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SCHALIENHOEVEDREEF 20T
- **CITY:** 2800 MECHELEN
- **PROVINCE COUNTRY:** C9

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GALAPAGOS NV
- **DATE OF NAME CHANGE:** 20071220

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2026**

Commission File Number: **001-37384**

**Lakefront Biotherapeutics**

(Translation of registrant's name into English)

**Schaliënhoevedreef 20T, 2800 Mechelen, Belgium**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Mr. Henry Gosebruch, included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

------

On June 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[Exhibit 99.1. Press release dated June 8, 2026](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Lakefront Biotherapeutics&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: June 9, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Annelies Denecker&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Annelies Denecker |
|  | Company Secretary |

---

**EXHIBIT 99.1**

**Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer**

**Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.**<sup>1</sup> **Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee.**

"Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues," said Henry Gosebruch, Chief Executive Officer of Lakefront. "The Ouro portfolio is now the cornerstone of Lakefront's R&D pipeline and I'm thrilled to have a talented drug developer of Eric's caliber and experience to guide the development of gamgertamig and our future clinical programs."

Dr. Hedrick has a twenty-five year track record successfully developing effective and commercially successful therapies in the pharmaceutical and biotechnology industry. Prior to joining Lakefront in July, 2025 to serve as clinical evaluation lead for new pipeline opportunities, Dr. Hedrick held roles as Chief Executive Physician at EQRx, Chief Advisor and Interim Chief Medical Officer for BeiGene, Chief Medical Officer at Epizyme and Interim Chief Medical Officer at Pharmacyclics. Dr. Hedrick started his career in biotechnology at Genentech. He received his M.D. from the University of Maryland and was previously an attending physician at the Memorial Sloan-Kettering Cancer Center.

**About Lakefront<sup>®</sup>** **Biotherapeutics**

Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

**Investor Relations** 

Sherri Spear

+1 412 522 6418<br> sherri.spear@lakefrontbio.com

**Forward-looking statements**

This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "will," "long-term," and "forward," and any similar expressions. These statements include, but are not limited to, statements regarding the announced leadership appointment; Mr. Hedrick's expected responsibilities and potential contributions to the company, and the company's strategic transformation and pipeline. Any forward-looking statements in this press release are based on our management's current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties, and other factors which might cause our actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties, and other factors include, without limitation, the risk that Lakefront will encounter challenges retaining or attracting talent, that our leadership transition may be disruptive to our business operations, and risks related to our ability to effectively transfer knowledge during this period of transition. A further list and description of these risks, uncertainties, and other factors can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless required by law or regulation.

------

<sup>1</sup> See GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - Lakefront Biotherapeutics for further details